BioSpace News Archive

Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into a definitive agreement with two institutional investors for the purchase and sale of 10,000,000 shares of the Company’s common stock

BDC Advisors, a healthcare strategy consulting firm, today announced the appointment of Pam Nicholson, a nationally recognized healthcare strategist and executive, as a Director and a leader of BDC’s Health Enterprise Strategy consulting practice

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the U.S. Food & Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for KAN-101, the company’s lead antigen-specific drug candidate.

GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) granted a priority review for the company’s Biologics License Application (BLA) seeking approval of belantamab mafodotin (GSK2857916) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.

Miach Orthopaedics, Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, announced that Stephen Wohlert, PhD, has joined the company as vice president of manufacturing.

Recognition marks Dow’s 15th consecutive year receiving a perfect score on the Foundation’s Corporate Equality Index

Henry Schein Earns 100 Percent on the Human Rights Campaign Foundation’s Annual Scorecard Assessing LGBTQ Workplace Equality

Zymergen, a science and material innovation company, today announced that it has appointed Jay Flatley, Chairman of the Board of Illumina, and Sandra E. Peterson, former Group Worldwide Chairman for Johnson & Johnson, to the Company’s Board of Directors, effective immediately.

The American College of Physicians (ACP), the nation’s second-largest physician group, claiming 159,000 members, has announced its support for “single-payer, public option plans.”

Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that Egan-Jones Proxy Services (“Egan-Jones”) has recommended shareholders vote for both HDF nominees on the Blue proxy card.